Beta-d-N4-Hydroxycytidine - D2

Beta-d-N4-Hydroxycytidine - D2 (NHC) is a nucleoside analog that is used in the treatment of various viral infections. It is a prodrug of the active metabolite, N4-hydroxycytidine (NHC), which inhibits viral replication by interfering with RNA synthesis. NHC is a cytidine analog that is structurally similar to other nucleoside analogs such as ribavirin and sofosbuvir. It is a broad-spectrum antiviral agent that has shown activity against a range of RNA viruses including coronaviruses, influenza viruses, and filoviruses. NHC is metabolized in the liver to its active form, N4-hydroxycytidine, which is incorporated into viral RNA during replication, leading to premature termination of the RNA chain. This disrupts viral replication and reduces the viral load in infected cells. NHC has been shown to be effective against a variety of viral infections in preclinical studies, including coronaviruses such as SARS-CoV-2. It has also been shown to be safe and well-tolerated in animal studies and clinical trials. In conclusion, Beta-d-N4-Hydroxycytidine - D2 is a promising antiviral agent that has shown activity against a range of RNA viruses. Its use in the treatment of viral infections may offer a new approach to combating these diseases and reducing their impact on public health.